Real world evidence (RWE) refers to data collected outside the context of traditional clinical trials, such as observational studies, registries, and electronic health records. RWE can provide valuable insights into the safety, effectiveness, and real-world use of drugs, and has the potential to transform drug development.
Some of the opportunities of real world evidence in drug development include:
1. Improved patient recruitment: RWE can help identify patient populations that are typically underrepresented in clinical trials, such as elderly patients, patients with multiple comorbidities, and those with rare diseases. This can help improve patient recruitment and enable more representative clinical trials.
2. Enhance clinical trial design: RWE can help inform the design of clinical trials, for example, by identifying appropriate endpoints, understanding patient demographics, and identifying potential confounding factors that need to be accounted for.
Identify safety concerns: RWE can help identify safety concerns that may not have been detected in clinical trials, especially those related to long-term use or rare adverse events. This can help improve post-marketing surveillance and ensure that drugs are used safely in the real world.
3. Better understanding of effectiveness: RWE can provide insights into the effectiveness of drugs in the real world, including how drugs are used in combination with other treatments, and how patient outcomes vary across different subpopulations.
4. Accelerate drug development: By leveraging RWE, drug development timelines can be accelerated as fewer resources are required for clinical trials, making it easier to conduct larger and more complex studies. Additionally, RWE can help optimize the design of clinical trials, reducing the likelihood of failed trials and resulting in faster regulatory approvals.
In summary, real world evidence has the potential to improve drug development in a number of ways, including patient recruitment, clinical trial design, safety monitoring, and accelerating drug development timelines. By leveraging RWE, drug developers can gain a better understanding of how drugs work in the real world, which can ultimately improve patient outcomes.
Share this story...
Real World Evidence (RWE) 101 – Parkinson’s Disease
RWE 101 - Parkinson’s Disease Real-world evidence (RWE) refers to clinical evidence regarding the usage and potential benefits or risks of a treatment derived from analysis of real-world data [...]
Real World Evidence (RWE) 101 – Benefits of RWE in the Context of Rare Diseases
RWE 101 - Benefits of RWE in the Context of Rare Diseases Real-world evidence (RWE) refers to information on health care that comes from real-world settings, such as electronic [...]
Real World Evidence (RWE) 101 – Disease Prevalence vs Incidence
RWE 101 - Disease Prevalence vs Incidence Real-world evidence (RWE), derived from real-world data (RWD), allows us to gain insights into disease prevalence and incidence outside of controlled clinical [...]
Real World Evidence (RWE) 101 – Principles for Ensuring that Research Results are Reliable, Valid, and Objective
RWE 101 - Principles for Ensuring that Research Results are Reliable, Valid, and Objective Ensuring that research results are reliable, valid, and objective requires careful planning, execution, and evaluation. [...]
Real World Evidence (RWE) 101 – Why Should Non-Interventional Studies NOT be Promotional?
RWE 101 - Why Should Non-Interventional Studies NOT be Promotional? Non-interventional studies (NIS) are designed to observe and analyze data from real-world clinical settings without intervening or manipulating any [...]
Real World Evidence (RWE) 101 – Seeding Studies
RWE 101 - Seeding Studies Seeding studies, in the context of real-world evidence (RWE), refer to studies that were conducted by pharmaceutical or medical device companies after a product's [...]







